to
be augmented by the launch later this year of our advanced CardioDrive II
model, which will be previewed at HRS, we see our recurring revenue stream
accelerating significantly in 2009. For that year, we have a goal of
approximately 20,000 procedures and expect to generate revenues per
procedure of more than $1,000 from a combination of royalties and
proprietary disposables to which will be added substantial service,
software license and network connection fees. Thus, we are gaining
confidence in our drive to profitability and believe that, once the
irrigated catheter is in full commercial release, the key elements of our
profitability will be per- procedure pricing power, rapidly accelerating
Odyssey sales, continued strong growth in Niobe system sales, and gross
margins on the order of 70%, coupled with continued focus on operating
expense control," concluded Mr. Hogg.
First Quarter Financial Performance
Gross margin for the quarter was 65% of revenue or $4.6 million,
similar to the 65% of revenue or $5.9 million realized in the first quarter
2007.
First quarter operating expenses increased 7% to $17.8 million in the
quarter, compared to $16.7 million in the first quarter of 2007. The
increase was driven by higher sales and marketing, and general and
administrative expenses.
R&D expenses for the three months ended March 31, 2008, decreased 17%
to $4.7 million, compared to $5.7 million in the same period in 2007. The
decrease is related to a reduction in expenses for new product
introductions and further device development.
The $17.8 million of total operating expenses for the three months
ended March 31, 2008 decreased by approximately $1.0 million compared to
the $18.9 million recorded in the three months ended December 31, 2007, in
line with the company's previously established objectives regarding overall
operating expense levels in 2008.
The Company reported a net loss for the first quarter of 2008 of $13.5
million,
'/>"/>
SOURCE Stereotaxis, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine news :1.
Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference2.
Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases3.
Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe4.
Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call5.
Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference6.
Stereotaxis Receives $20 Million in Additional Loan Commitments7.
Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook8.
Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System9.
Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System10.
Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System11.
Kaiser Foundation Health Plan and Hospitals Reports First Quarter 2008 Financial Results